healio.com /2 weeks ago

Zanidatamab regimens improve survival for gastroesophageal cancer

First-line zanidatamab-hrii plus chemotherapy, without or with tislelizumab-jsgr, extended survival 24% and 35% vs. trastuzumab plus chemotherapy for those with locally advanced or...

Read source
bioengineer.org /1 week ago

Immunotherapy Combined With Chemotherapy Extends Survival in Advanced SMARCA4-Deficient Lung Cancer

A real-world retrospective study demonstrates that adding first-line immunotherapy to chemotherapy significantly prolongs median overall survival by 23 months in advanced SMARCA4-d...

Read source
cafepharma.com /2 weeks ago

Chemotherapy Actually Helps Immunotherapy in Cancer

Chemotherapy Actually Helps Immunotherapy in Cancer Anonymous (not verified) Mon, 11/02/2026 - 18:25 pharmagather item url Chemotherapy Actually Helps Immu...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.